| Drug Name |
Tizanidine hydrochloride |
| Drug ID |
BADD_D02231 |
| Description |
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.
Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label]. |
| Indications and Usage |
For the management of increased muscle tone associated with spasticity |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
M03BX02 |
| DrugBank ID |
DB00697
|
| KEGG ID |
D00776
|
| MeSH ID |
C023754
|
| PubChem ID |
114869
|
| TTD Drug ID |
D01MDT
|
| NDC Product Code |
55111-020; 70515-604; 59651-315; 75834-207; 50742-224; 60505-2648; 50742-226; 60505-2650; 59651-316; 49884-611; 50742-225; 70771-1068; 70771-1069; 63629-2466; 70515-594; 0591-2788; 60505-2649; 55289-784; 55700-789; 42291-811; 70515-602; 75834-209; 0185-4400; 71209-064; 49999-347; 0591-2789; 70710-1113; 62332-492; 42291-812; 46708-491; 63278-0489; 72888-002; 38779-2351; 71209-065; 53747-003; 66022-0202; 71335-0317; 46708-492; 72888-001; 62332-493; 65015-777; 45865-954; 0591-2790; 71335-1698; 61919-196; 70710-1111; 59746-672; 72888-003; 59651-314; 63629-5139; 55700-865; 62332-491; 49884-719; 70515-606; 63629-2494; 75834-208; 63629-6537; 51927-0020; 0185-0034; 59746-670; 71610-114; 42291-810; 49884-765; 46708-493; 59746-671; 70710-1112; 70771-1067; 71209-066; 63629-2467 |
| Synonyms |
tizanidine | 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole | Zanaflex | tizanidine hydrochloride | tizanidine monohydrochloride | DS 103-282 | Sirdalud |
